BCA
RPRX icon

Berman Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Berman Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$33K Buy
920
+817
+793% +$31.8K 0.01% 833
2021
Q2 		$4K Buy
+103
New +$4.38K ﹤0.01% 1422

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Berman Capital Advisors's RPRX Position: Q3 2021 in Review

Berman Capital Advisors increased its Royalty Pharma (RPRX) stake by 793% in Q3 2021, buying an estimated $31.8K and bringing the position to 920 shares worth $33K. The position accounts for 0.01% of the portfolio, ranked #833.

Berman Capital Advisors first reported a position in RPRX in Q2 2021 and has held it in 2 quarters since. 232 funds tracked by Wall St. Rank hold RPRX as of Q3 2021.

  • Berman Capital Advisors held 920 shares of Royalty Pharma worth $33K as of Q3 2021.
  • Berman Capital Advisors bought 817 Royalty Pharma shares in Q3 2021, an estimated $31.8K.
  • Royalty Pharma made up 0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #833 holding.
  • Berman Capital Advisors first reported a position in Royalty Pharma in Q2 2021 and has held it in 2 quarters since.
  • 232 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.